The Role of Biomarkers in the Diagnosis and Management of Heart Failure

Haitham Shoman and Samer Ellahham*
Cleveland Clinic Foundation & Sheikh Khalifa Medical City, Cleveland Clinic, USA

Submission: February 10, 2017; Published: March 23, 2017

*Corresponding author: Samer Ellahham, Cleveland Clinic Foundation & Sheikh Khalifa Medical City, Cleveland Clinic, USA, Email: Samerellahham@yahoo.com

Abstract
Heart failure is a growing challenge both in diagnosis and management globally. Current diagnostic tools have several merits and limitations and the field is in dying need for effective and efficient biomarkers. Emerging biomarkers show promising evidence of revolutionizing the early diagnosis and management of heart failure by cardiologists and non-specialists. Biomarkers are classified according to myocyte changes such as biomarkers in myocyte stress, injury and necrosis, ischemia and fibrosis. In addition, there are biomarkers in heart failure associated with infections, renal dysfunction and neurohormonal biomarkers. This article will briefly discuss key biomarkers with major evidence to galvanize medical field interest in this remarkable field.

Keywords: Heart failure; Biomarkers; BNP; NT-proBNP; MR-proANP; MR-proADM; Troponin; GDF-15; Procalcitonin; Gal-3.

Introduction
Heart failure (HF) diagnosis and management remains a topic of concern across the world despite the wealth of knowledge on the heart’s pathophysiology. Around 8-12% is the risk of mortality from HF and this is still on the rise despite high end technological advancement [1]. Early diagnosis and management remains the gold standard to prevent adverse events and this is why there is a shift toward early diagnostic tools such as the biomarkers. Since current diagnostic tools are in short of sensitivity and specificity, biomarkers have gained significant attention within the last decades owing to their strength in early diagnosis, risk stratification, high sensitivity and specificity and disease progression in patients with HF [2,3]. In order for biomarkers to be used in current practice, they should show severity of ongoing disease and response to treatment to be able to tailor treatment for every individual. This article will offer a brief overview of the role of the biomarkers in the management of heart failure.

Biomarkers in Heart Failure
Myocyte stress biomarkers

**B- Natriuretic Peptide (BNP):** BNP is primarily released from the ventricular myocardium mainly due to left ventricular dysfunction, dilated and hypertrophic ventricles, increased wall tension and increase in intracardiac pressure [4,5]. Pulmonary wedge capillary pressure, pulmonary hypertension and congestive heart failure (CHF) also cause significant changes in BNP levels [4,6].

BNP can act against the physiological abnormalities of heart failure by causing responses as arterial vasodilation, diuresis, natriuresis and reducing the activities of renin-angiotensin-aldosterone system along with the sympathetic nervous system [7]. HF is unlikely in BNP <100pg/ml and is very likely to be present with BNP >400pg/ml while patients with BNP 100-400pg/ml are considered to be within the gray zone [8]. BNP measurement has shown to be very useful in diagnosing and evaluating patients with HF presenting with dyspnea in the emergency department [7,9]. BNP levels are also used in the diagnosis and risk stratification of patients with chronic heart failure and prognosis of patients with HF. In addition, they are used for admission, in-hospital and discharge assessment of patients to evaluate morbidity, mortality and readmission risks [6]. Pre-discharge levels of >600pg/ml indicates intensified treatment prior to discharge [10].
Amino-terminal pro-brain natriuretic peptide (NT-proBNP): NT-proBNP is a biomarker for HF and patients suffering from chronic ischemic left ventricular dysfunction [11]. Besides being a biomarker representing the patient’s condition and guiding therapy, it is considered cost-effective and can be used to guide HF therapy since it was found that 3-year mortality was reduced in patients under NT-proBNP guided treatment [6,12]. Due to its long half-life, NT-proBNP is considered a more precise index for ventricular stress and a better prognosis and outcomes predictor than BNP [7].

Midregional pro atrial natriuretic peptide (MR-proANP): MR-proANP is a stronger biomarker providing diagnostic and prognostic information along with regular natriuretic peptide tests for assessing congestive heart failure (CHF) [13]. Adding MR-proANP BNP and NT-proBNP testing increases the diagnostic accuracy of tests especially with obesity, old age, renal dysfunction and gray zone values, hence it is a robust analyte in HF diagnosis and reducing mortality, morbidity, treatment costs and it is very useful in risk stratification [6]. Due to its higher biological stability, MR-proANP is more superior to BNP and NT-proBNP in death prediction in CHF.

Midregional pro adrenomedullin (MR-proADM): MR-proADM outperforms BNP and NT-proBNP in predicting mortality within 90 days [14]. It is also a robust tool in risk stratification of patients with acute and chronic HF and is associated with higher risks of both morbidity and mortality [15,16]. Despite some studies suggesting the robustness of MR-proADM, more work is still needed to define its complete role in the clinical setting and HF management.

Myocyte injury/necrosis biomarkers

Cardiac Troponins (cTn): cTnT is found to be occurring in left ventricular (LV) hypertrophy and systolic dysfunction while cTnI is associated with impaired hemodynamics, LV dysfunction, elevated BNP and higher mortality [6,17,18]. More studies are needed to look at the long term predictability of cTn [6].

Myocyte ischemia biomarkers

Growth Differentiation Factor-15 (GDF-15): GDF-15 is found to be increased in patients who died after acute myocardial infarction especially in myocardial areas with irreversible damages [19]. It was also found to be associated with reduced endothelium-dependent vasodilation in resistance vessels, plaque burden, LV mass and hypertrophy, coronary artery disease and HF [20]. GDF-15 acts as a protective agent in hypertrophy and injury of the cardiac muscle [19]. It has been shown to be a strong predictor for all cause, cardiovascular and non-cardiovascular mortality outweighing NT-proBNP or C-reactive protein in HF patients [21].

Renal dysfunction biomarker

Neutrophil Gelatinase-Associated Lipocalin (NGAL): In HF, the heart and kidney are both affected and NGAL is an exceptional biomarker to be used in patients with kidney injuries since it is found in urine [22-24]. NGAL is helpful for clinicians to tailor HF therapy based on the patients’ renal function more effectively and avoid the use of nephrotoxic drugs [6]. In patients with acute decompensated HF (ADHF) and high NGAL levels, there is increased morbidity and mortality. In addition, those with increased levels of NGAL and BNP carry the worst prognosis [25].

HF with infection biomarker

Procalcitonin (PCT): PCT is a biomarker found in the circulation as a result of bacterial endotoxins and infections such as underlying pneumonia [26]. It was found to be useful in allowing clinicians to initiate the appropriate antibiotic therapy and hence reduce the risk of morbidity and mortality [27]. PCT helps in differentiating between cardiac and non-cardiac dyspnea. It helps in increasing the diagnostic accuracy of underlying infections where PCT levels >0.25ng/ml require antibiotics and levels <0.5ng/ml did not [6]. To further increase diagnostic accuracy, PCT can be added to BNP in patients with HF and suspecting underlying pneumonia. More randomized controlled trials would be needed to lay out its exact role in therapy guidance.

Neurohormonal biomarker

Copeptin: In patients with HF following an acute myocardial infarction, copeptin was found to be a strong biomarker of morbidity related cardiovascular events and mortality [28]. A study showed that adding copeptin to MR-proADM produced best results in predicting 14-day mortality [15]. There is emerging evidence that copeptin has a great prognostic potential to HF, but more clinical trials are needed to further define its role in HF management.

Myocyte fibrosis biomarker

ST2: ST2, a novel biomarker, is independent from natriuretic peptides giving it a unique predictive value for HF. Its prognostic strength could be increased when associated with other natriuretic peptides [29]. It is useful in risk stratification and its levels are higher in patients who died within a year of diagnosis [6]. Levels of >0.20ng/ml show higher risk of mortality in patients with or without HF [30]. ST2 is relatively a new biomarker and future studies are necessary to assist in its role in guiding HF management.

Galectin-3 (Gal-3): Raised Gal-3 levels are seen in cardiac hypertrophy, fibrosis, remodeling, ventricular dysfunction and ADHF and are the strongest predictors of 60-day mortality compared to some natriuretic peptides [31,32]. In order to increase diagnostic and prognostic accuracy, adding Gal-3 to NT-proBNP yield better results [32]. A study suggests that ventricular remodeling shows higher Gal-3 linked to LV end diastolic volume changes [33]. Unlike natriuretic peptides that are increased in HF severity, Gal-3 reflects interstitial fibrosis.
and pathophysiological changes independent of HF severity [34]. Thus it can be seen prior to clinically evident HF making it useful in prediction and prevention of the disease. Studies show that Gal-3 could also be helpful in the guidance of HF management.

This is a short review article to give an overview of the available and emerging biomarkers. It is meant to be a highlight rather than an in-depth review.

Conclusion

Heart failure is a growing epidemic worldwide. There are several challenges still existing in diagnosis and management. The emerging field of biomarker research is promising and deserves utmost attention. This mini-review is conducted to give a highlight about this promising field. The authors have no doubt that while it is a long journey, the field of biomarkers has added and will provide a groundbreaking methodology in early diagnosis and optimal management of heart failure. Outcome based research through randomized controlled clinical trials will certainly position biomarkers in heart failure in most relevant clinical practice guidelines.

References

1. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, et al. (2008) Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 156(4): 662-673.
2. Rollath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, et al. (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med 37(4): 619-626.
3. Morrow DA, de Lemos JA (2007) Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 115(8): 949-952.
4. Yasue H, Yoshimura M, Sumida H, Kikutaka K, Kugiyama K, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90(1): 195-203.
5. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, et al. (2002) B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106(4): 416-422.
6. Choudhary R, Iqbal N, Khusro F, Higginbotham E, Green E, et al. (2013) Heart failure biomarkers. J Cardiovasc Transl Res 6(4): 471-484.
7. Braunwald E (2008) Biomarkers in Heart Failure. N Engl J Med 358(20): 2148-2159.
8. Brenden CK, Hollander JE, Guse D, McCullough PA, Nowak R, et al. (2006) Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. Am Heart J 151(5): 1006-1011.
9. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3): 161-167.
10. Logeswar D, Thabat G, Jourdain P, Chavelas C, Beyne P, et al. (2004) PredischARGE B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43(4): 635-641.
11. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, et al. (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37(2): 1781-1787.
12. Lainchbury JG, Troughton RW, Strongman KM, Frampton CM, Pilbrow A, et al. (2009) N-Terminal Pro-B-Type Natriuretic Peptide Guided Treatment for Chronic Heart Failure: Results From the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial. J Am Coll Cardiol 55(1): 53-60.
13. Mogenthaler NG, Struck J, Thomas B, Bergmann A (2004) Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human Plasma. Clin Chem 50(1): 234-236.
14. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, et al. (2010) Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea: Results From the BACH (Biomarkers in Acute Heart Failure) Trial. J Am Coll Cardiol 55(19): 2062-2076.
15. Peacock WF, Nowak, R, Christenson R, DiSomma S, Neath SX, et al. (2011) Short-term Mortality Risk in Emergency Department Acute Heart Failure. Acad Emerg Med 18(9): 947-956.
16. von Haehling S, Filippatos GS, Papassotiropoulos A, Gwozda M, Jankowska EA, et al. (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12(5): 484-491.
17. Dinh W, Nicki W, Firth R, Lankisch P, Hess G, et al. (2011) High sensitive troponin T and heart kidney acid binding protein: Novel biomarker in heart failure with normal ejection fraction? A cross-sectional study. BMC Cardiovasc Disord 11(1): 41.
18. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, et al. (2009) Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays. N Engl J Med 361(9): 858-867.
19. Kempf T, Eden M, Strelau J, Naguib M, Willembockel C, et al. (2006) The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury. Circ Res 98(3): 351-360.
20. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, et al. (2009) Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 30(19): 2346-2353.
21. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Conner E (2011) Growth-Differentiation Factor-15 Is a Robust, Independent Predictor of 11-Year Mortality Risk in Community-Dwelling Older Adults Clinical Perspective. Circulation 123(19): 2101-2110.
22. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, et al. (2011) The Outcome of Neutrophil Gelatins-Associated Lipocalin-Positive Subclinical Acute Kidney Injury: A Multicenter Pooled Analysis of Prospective Studies. J Am Coll Cardiol 57(17): 1752-1761.
23. Nickolas TL, Schmidt-Ott KM, Canetta P, Forster C, Singer E, et al. (2012) Diagnostic and Prognostic Stratification in the Emergency Department Using Urinary Biomarkers of Nephron Damage: A Multicenter Prospective Cohort Study. J Am Coll Cardiol 59(3): 246-255.
24. Aghel A, Shrestha K, Mullens W, BorowskiA, Tang WHW (2010) Serum Neutrophil Gelatins-Associated Lipocalin (NGAL) in Predicting Worsening Renal Function in Acute Decompensated Heart Failure. J Card Fail 16(1): 49-54.
25. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, et al. (2011) Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure. The NGAL Evaluation Along with B-type Natriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 13(8): 846-851.
Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin I, et al. (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341(8844): 515-518.

Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, et al. (2012) Cardiac Complications in Patients With Community-Acquired Pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 125(6): 773-781.

Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, et al. (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30(10): 1187-1194.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, et al. (2002) Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction. Circulation 106(23): 2961-2966.

Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, et al. (2007) Measurement of the Interleukin Family Member ST2 in Patients with Acute Dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50(7): 607-613.

Sharma UC, Pokharel S, van Braekel TJ, van Berlo JH, Cleutjens JPM, et al. (2004) Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction. Circulation 110(19): 3121-3128.

van Kinnen-and RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, et al. (2006) Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. J Am Coll Cardiol 48(6): 1217-1224.

Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, et al. (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102(2): 109-110.

Gopal DM, Kommineni M, Ayakon N, Koebel C, Ayakon R, et al. (2012) Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure. J Am Heart Assoc 1(5): e000760.

This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/JOCCT2017.04.555626

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php